MOTS-c reduces myostatin and muscle atrophy signaling.

Obesity and type 2 diabetes are metabolic diseases, often associated with sarcopenia and muscle dysfunction. MOTS-c, a mitochondrial-derived peptide, acts as a systemic hormone and has been implicated in metabolic homeostasis. Although MOTS-c improves insulin sensitivity in skeletal muscle, whether MOTS-c impacts muscle atrophy is not known. Myostatin is a negative regulator of skeletal muscle mass and also one of the possible mediators of insulin resistance-induced skeletal muscle wasting. Interestingly, we found that plasma MOTS-c levels are inversely correlated with myostatin levels in human subjects. We further demonstrated that MOTS-c prevents palmitic acid-induced atrophy in differentiated C2C12 myotubes, while MOTS-c administration decreased myostatin levels in plasma in diet-induced obese mice. By elevating AKT phosphorylation, MOTS-c inhibits the activity of an upstream transcription factor for myostatin and other muscle wasting genes, FOXO1. MOTS-c increases mTORC2 and inhibits PTEN activity, which modulates AKT phosphorylation. Further upstream, MOTS-c increases CK2 activity, which leads to PTEN inhibition. These results suggest that through inhibition of myostatin, MOTS-c could be a potential therapy for insulin resistance-induced skeletal muscle atrophy as well as other muscle wasting phenotypes including sarcopenia.

[1]  James H. Joly,et al.  Mitochondrial-Encoded Peptide MOTS-c is an Exercise-Induced Regulator of Aging Metabolic Homeostasis and Physical Capacity , 2019, bioRxiv.

[2]  A. Stewart,et al.  Changes in Plasma Free Fatty Acids Associated with Type-2 Diabetes. , 2019 .

[3]  P. Cohen,et al.  The mitochondrial‐derived peptide MOTS‐c is a regulator of plasma metabolites and enhances insulin sensitivity , 2019, Physiological reports.

[4]  F. López‐Soriano,et al.  Therapeutic strategies against cancer cachexia , 2019, European journal of translational myology.

[5]  T. Shan,et al.  Roles of phosphatase and tensin homolog in skeletal muscle , 2018, Journal of cellular physiology.

[6]  K. Fabianowska-Majewska,et al.  Relationship of muscle function to circulating myostatin, follistatin and GDF11 in older women and men , 2018, BMC Geriatrics.

[7]  J. Batsis,et al.  Sarcopenic obesity in older adults: aetiology, epidemiology and treatment strategies , 2018, Nature Reviews Endocrinology.

[8]  A. Hoffman,et al.  Mitochondrial peptides modulate mitochondrial function during cellular senescence , 2018, Aging.

[9]  Q. Ning,et al.  Circulating MOTS‐c levels are decreased in obese male children and adolescents and associated with insulin resistance , 2018, Pediatric diabetes.

[10]  J. Galgani,et al.  Plasma MOTS-c levels are associated with insulin sensitivity in lean but not in obese individuals , 2018, Journal of Investigative Medicine.

[11]  J. Backman,et al.  Prevention of chemotherapy‐induced cachexia by ACVR2B ligand blocking has different effects on heart and skeletal muscle , 2017, Journal of cachexia, sarcopenia and muscle.

[12]  S. Banni,et al.  Palmitic Acid: Physiological Role, Metabolism and Nutritional Implications , 2017, Front. Physiol..

[13]  I. Kettelhut,et al.  Myostatin promotes distinct responses on protein metabolism of skeletal and cardiac muscle fibers of rodents , 2017, Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologicas.

[14]  Jae‐Young Lim,et al.  Oleate Prevents Palmitate-Induced Atrophy via Modulation of Mitochondrial ROS Production in Skeletal Myotubes , 2017, Oxidative medicine and cellular longevity.

[15]  L. Grunnet,et al.  MECHANISMS IN ENDOCRINOLOGY: Skeletal muscle lipotoxicity in insulin resistance and type 2 diabetes: a causal mechanism or an innocent bystander? , 2017, European journal of endocrinology.

[16]  Yaohui Nie,et al.  Pten is necessary for the quiescence and maintenance of adult muscle stem cells , 2017, Nature Communications.

[17]  Ksenia V Lezhnina,et al.  New function of the myostatin/activin type I receptor (ALK4) as a mediator of muscle atrophy and muscle regeneration , 2016, Neuromuscular Disorders.

[18]  S. Nahashon,et al.  Molecular Mechanisms of Obesity-Induced Osteoporosis and Muscle Atrophy , 2016, Front. Physiol..

[19]  F. Ezquer,et al.  High Fat Diet-Induced Skeletal Muscle Wasting Is Decreased by Mesenchymal Stem Cells Administration: Implications on Oxidative Stress, Ubiquitin Proteasome Pathway Activation, and Myonuclear Apoptosis , 2016, Oxidative medicine and cellular longevity.

[20]  P. Atherton,et al.  Insulin resistance and sarcopenia: mechanistic links between common co-morbidities. , 2016, The Journal of endocrinology.

[21]  Jinxue Ruan,et al.  A long-term high-fat, high-sucrose diet in Bama minipigs promotes lipid deposition and amyotrophy by up-regulating the myostatin pathway , 2016, Molecular and Cellular Endocrinology.

[22]  W. Mitch,et al.  Inhibition of myostatin in mice improves insulin sensitivity via irisin-mediated cross talk between muscle and adipose tissues , 2015, International Journal of Obesity.

[23]  Changhan Lee,et al.  The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistance. , 2015, Cell metabolism.

[24]  G. Rassidakis,et al.  SIN1, a critical component of the mTOR-Rictor complex, is overexpressed and associated with AKT activation in medullary and aggressive papillary thyroid carcinomas. , 2014, Surgery.

[25]  B. Lin,et al.  Myostatin inhibitors as therapies for muscle wasting associated with cancer and other disorders , 2013, Current opinion in supportive and palliative care.

[26]  N. Binkley,et al.  Myostatin – The Holy Grail for Muscle, Bone, and Fat? , 2013, Current Osteoporosis Reports.

[27]  L. Oyama,et al.  Lipotoxicity: Effects of Dietary Saturated and Transfatty Acids , 2013, Mediators of inflammation.

[28]  D. Tindall,et al.  Regulation of FOXO protein stability via ubiquitination and proteasome degradation. , 2011, Biochimica et biophysica acta.

[29]  G. Boden.  Obesity, insulin resistance and free fatty acids , 2011, Current opinion in endocrinology, diabetes, and obesity.

[30]  Zhiyong Cheng,et al.  Targeting Forkhead box O1 from the concept to metabolic diseases: lessons from mouse models. , 2011, Antioxidants & redox signaling.

[31]  B. Loos,et al.  Diet‐induced obesity alters signalling pathways and induces atrophy and apoptosis in skeletal muscle in a prediabetic rat model , 2011, Experimental physiology.

[32]  P. Biga,et al.  Myostatin Expression, Lymphocyte Population, and Potential Cytokine Production Correlate with Predisposition to High-Fat Diet Induced Obesity in Mice , 2010, PloS one.

[33]  J. Girard,et al.  Increased Mitochondrial Fatty Acid Oxidation Is Sufficient to Protect Skeletal Muscle Cells from Palmitate-induced Apoptosis* , 2010, The Journal of Biological Chemistry.

[34]  W. Mitch,et al.  PTEN Inhibition Improves Muscle Regeneration in Mice Fed a High-Fat Diet , 2010, Diabetes.

[35]  A. Hevener,et al.  Examination of ‘lipotoxicity’ in skeletal muscle of high‐fat fed and ob/ob mice , 2009, The Journal of physiology.

[36]  F. Vazquez,et al.  A phosphorylation-dependent intramolecular interaction regulates the membrane association and activity of the tumor suppressor PTEN , 2009, Proceedings of the National Academy of Sciences.

[37]  D. Hittel,et al.  Increased Secretion and Expression of Myostatin in Skeletal Muscle From Extremely Obese Women , 2009, Diabetes.

[38]  Yan Wang,et al.  Bax signaling regulates palmitate-mediated apoptosis in C(2)C(12) myotubes. , 2008, American journal of physiology. Endocrinology and metabolism.

[39]  B. Vernus,et al.  Myostatin in the Pathophysiology of Skeletal Muscle , 2007, Current genomics.

[40]  W. Mitch,et al.  PTEN Expression Contributes to the Regulation of Muscle Protein Degradation in Diabetes , 2007, Diabetes.

[41]  L. Kuller,et al.  Accelerated Loss of Skeletal Muscle Strength in Older Adults With Type 2 Diabetes , 2007, Diabetes Care.

[42]  D. Allen,et al.  Regulation of myostatin expression and myoblast differentiation by FoxO and SMAD transcription factors , 2007 .

[43]  J. Qin,et al.  SIN1/MIP1 Maintains rictor-mTOR Complex Integrity and Regulates Akt Phosphorylation and Substrate Specificity , 2006, Cell.

[44]  A. Newman,et al.  Decreased Muscle Strength and Quality in Older Adults With Type 2 Diabetes , 2006, Diabetes.

[45]  G. Bray,et al.  A high-fat diet coordinately downregulates genes required for mitochondrial oxidative phosphorylation in skeletal muscle. , 2005, Diabetes.

[46]  G. Boden.  Free fatty acids and insulin secretion in humans , 2005, Current diabetes reports.

[47]  T. Khurana,et al.  Myostatin propeptide‐mediated amelioration of dystrophic pathophysiology , 2005, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[48]  C. Kahn,et al.  Muscle-Specific Pten Deletion Protects against Insulin Resistance and Diabetes , 2005, Molecular and Cellular Biology.

[49]  Marco Sandri,et al.  Foxo Transcription Factors Induce the Atrophy-Related Ubiquitin Ligase Atrogin-1 and Cause Skeletal Muscle Atrophy , 2004, Cell.

[50]  L. Helman,et al.  Levels of PTEN protein modulate Akt phosphorylation on serine 473, but not on threonine 308, in IGF-II-overexpressing rhabdomyosarcomas cells , 2003, Oncogene.

[51]  G. Boden.  Effects of free fatty acids (FFA) on glucose metabolism: significance for insulin resistance and type 2 diabetes. , 2003, Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association.

[52]  R. Ahima,et al.  Functional improvement of dystrophic muscle by myostatin blockade , 2002, Nature.

[53]  R. Pulido,et al.  The Tumor Suppressor PTEN Is Phosphorylated by the Protein Kinase CK2 at Its C Terminus , 2001, The Journal of Biological Chemistry.

[54]  Francisca Vazquez,et al.  Phosphorylation of the PTEN Tail Regulates Protein Stability and Function , 2000, Molecular and Cellular Biology.

[55]  Se-Jin Lee,et al.  Regulation of skeletal muscle mass in mice by a new TGF-p superfamily member , 1997, nature.